We are live on ! Find out more
INKT icon

MiNK Therapeutics
INKT

16 hedge funds and large institutions have $1.7M invested in MiNK Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more capital invested

Capital invested by funds: $1M → $1.7M (+$701K)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

45% more funds holding

Funds holding: 11 → 16 (+5)

0.53% more ownership

Funds ownership: 1.41% → 1.93% (+0.53%)

Holders
16
Holders Change
+5
Holders Change %
+45.45%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SG
StoneX Group
New York
+$49.6K
2
Millennium Management
Millennium Management
New York
+$25.5K
3
UBS Group
UBS Group
Switzerland
+$5.26K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.98K
5
BlackRock
BlackRock
New York
+$1.15K

Top Sellers

Rank Fund Capital Flow
1
JMPWA
JP Morgan Private Wealth Advisors
California
-$68.1K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$563

INKT Hedge Fund Activity: Q4 2022 in Review

16 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q4 2022, worth a combined $1.7M — up 70% from $1M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new INKT positions and 0 closed out — a net gain of 5 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was StoneX Group, opening a new position worth an estimated $49.6K. The largest seller was JP Morgan Private Wealth Advisors, cutting an estimated $68.1K.

  • 16 institutional investors held MiNK Therapeutics (INKT) as of Q4 2022, up from 11 in Q3 2022.
  • Funds reported $1.7M of MiNK Therapeutics stock for Q4 2022, up 70% quarter-over-quarter.
  • 5 funds opened new MiNK Therapeutics positions in Q4 2022 and 0 closed out, a net change of +5 holders.
  • The largest MiNK Therapeutics buyer in Q4 2022 was StoneX Group, an estimated $49.6K added.
  • The largest MiNK Therapeutics seller in Q4 2022 was JP Morgan Private Wealth Advisors, an estimated $68.1K sold.

Based on aggregated 13F filings for Q4 2022.